# MenB Vaccine Does Not Protect Against Gonorrhoea, Study Finds
Researchers have determined that the Meningitis B vaccine provides no protection against gonorrhoea infections, contradicting earlier assumptions that guided public health recommendations.
The vaccine, which targets meningococcal disease caused by the Neisseria meningitidis bacterium, was offered to at-risk men based on earlier evidence suggesting cross-protection against gonorrhoea. That bacterium, Neisseria gonorrhoeae, shares structural similarities with meningococcus, prompting health officials to hypothesize that immunity against one might prevent the other.
This new major study refutes that theory. The findings demonstrate that vaccination does not reduce gonorrhoea infection rates in vaccinated men, even those at higher risk for sexually transmitted infections.
The result raises questions about resource allocation in sexual health programs. Gonorrhoeae has become increasingly resistant to antibiotics, creating a public health crisis. The World Health Organization classifies antibiotic-resistant gonorrhoea as a high-priority pathogen. Without an effective vaccine and with dwindling treatment options, prevention relies heavily on safer sex practices, regular testing, and prompt treatment with remaining antibiotics.
Health authorities now face pressure to reconsider vaccination strategies. Men seeking STI prevention cannot rely on MenB vaccination for gonorrhoea protection and must continue practicing safer sex, using condoms, and obtaining regular screening.
The study underscores how bacterial similarity alone does not guarantee cross-protection. While the meningococcal and gonococcal bacteria share genetic material, immune response differs significantly between the two infections. Understanding these distinctions helps researchers develop more targeted vaccines.
This finding comes as gonorrhoea cases rise globally. Public health officials emphasize that vaccination remains essential for meningococcal disease prevention, but men